DELEX ROADMAP:
A Future of Growth and Innovation
STRONG VISIONARY LEADERSHIP
With a proven track record of success, a strong visionary leadership team, and a strategic expansion plan that spans multiple facets of the healthcare industry, DELEX is poised to become a dominant player in the global healthcare market. As the company continues to innovate, expand, and strengthen its presence in key sectors, it remains on track to achieve its ambitious goals and deliver value to its stakeholders. The future of DELEX looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey.
ABOUT DELEX
DELEX is a Delaware-registered company engaged in the development and distribution of pharmaceutical and healthcare products through its associate channels, DELEX Pharma, in collaboration with JMN Brothers Pharma Limited, Inc. and DLX Holdings, Inc. DELEX focuses on delivering high-quality products across various sectors of the healthcare industry by leveraging its extensive network and strategic partnerships. Together with its associates, DELEX strives to meet the growing demands of the market while adhering to the highest standards of regulatory compliance and customer service excellence
STRENGTHS & GROWTH PLANS
A closer look at the strengths and growth plans designed to propel its success well into the future and drive innovation, growth, market leadership in the healthcare sector.
1. 15 Years of Robust Business Growth
DELEX Pharma’s legacy is built on 15 years of sustained growth, ranking as the third-largest national player in the hospital channel market according to IQVIA. The company’s leadership team, with over three decades of experience in the healthcare sector, has played an integral role in driving this growth and positioning DELEX as a powerhouse within the industry.
2. Strong Leadership That Drives Excellence
At the helm of DELEX is a group of seasoned leaders with extensive experience in both the pharmaceutical and medical industries. Their entrepreneurial acumen and expertise, honed through years of working with multinational healthcare giants, empower DELEX to continually adapt and thrive in a competitive market. This leadership ensures the company’s future success as they continue to execute on their ambitious vision for the future.
3. Holder of Various FDA Business Licenses & Permits
From importing and distributing pharmaceutical products to running drugstores and medical devices, DELEX is fully equipped to meet the regulatory standards that govern the diverse landscape of the Philippine healthcare industry. DELEX Pharma currently holds various licenses and permits issued by the Philippines Food and Drug administration for (i) Importer/ Wholesaler/Distributor of Drugs (ii) Importer of Medical Devices (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler and (v) Drugstore Operator, including Online Order and Delivery.
4. Holder of 30 FDA Approved Hospital Products
DELEX Pharma is committed to continuously expanding its product portfolio to meet the needs of both healthcare professionals and patients. With over 30 FDA-approved hospital products and numerous medical device products, DELEX is pushing the boundaries of innovation. The company’s recent launch of 11 new pharmaceutical products and strategic partnerships with multinational medical device firms demonstrates its aggressive expansion strategy across multiple therapeutic and diagnostic areas.
5. Expanding the Distribution Channels
With a network that already supplies nearly 700 hospitals nationwide and has established a foothold in over 900 Mercury Drug branches, DELEX is positioned for even greater reach. By building on its strong distribution network and forming strategic partnerships with healthcare providers, DELEX aims to expand its footprint, enhancing its market development and creating integrated healthcare solutions to improve patient outcomes.
6. Expanding the Medical Device Business
The medical device market in the Philippines is experiencing rapid growth, and DELEX is well-positioned to capitalize on this opportunity. With a strategic alliance with leading international companies such as Amsino, Masimo, and Verathon, DELEX aims to be a key player in the medical device sector. These collaborations will not only enhance DELEX’s offerings but also solidify its position as a leading distributor of high-quality healthcare solutions.
7. Expanding the Pharmacy Stores
Building on the success of its first pharmacy branch opened in 2021, DELEX plans to expand its retail pharmacy business to 60 locations in the coming years. This expansion comes at a time when the pharmacy market is poised for significant growth, driven by increased demand for pharmaceutical services and products. DELEX’s strategy of situating drugstores near hospitals and high-traffic areas is a smart move to generate strong sales and meet the needs of the community.
8. Expanding the Online Pharmacy Business
As the healthcare landscape becomes increasingly digital, DELEX is tapping into the rapidly growing ePharmacy market. Through its online platform, DELEX offers a seamless 24/7 ordering and delivery service for a wide range of over-the-counter medicines, prescription drugs, and health products. As the Philippines’ ePharmacy market continues to expand, DELEX is set to capture a broad customer base and meet the demand for convenient, cost-effective healthcare solutions.
9. Expand DELEX’s Training Programs and Global Networks
DELEX has proven its commitment to improving healthcare outcomes through educational initiatives such as the DELEX ICU Forum. What began as an in-person event has grown into a powerful online platform that has attracted nearly 200,000 healthcare professionals worldwide. The forum facilitates important conversations on critical care advancements, treatment protocols, and best practices, further solidifying DELEX’s role as a thought leader in the healthcare space.
10. Strategic Acquisition to Expand DELEX’s Product Portfolio
In 2022, DELEX Pharma made a significant move to acquire JMN Brothers Pharma Limited, a company known for its expertise in women’s health and beauty. This acquisition enables DELEX to expand its hospital product portfolio and tap into new market segments, further diversifying its offerings and increasing its market share in the healthcare sector.
11. Commitment to Quality Through ISO Certification
DELEX Pharma’s commitment to quality and operational excellence has been recognized globally. The company recently underwent and passed the ISO 9001:2015 re-certification, underscoring its dedication to meeting international quality standards and providing superior products and services to its customers.
12. Strong Distribution and Warehouse Capabilities
With a robust infrastructure that includes a dedicated trade sales team and state-of-the-art SAP ERP systems, DELEX Pharma ensures efficient distribution and inventory management. This operational efficiency allows DELEX to respond promptly to customer demands and maintain high levels of service across its entire distribution network.
13. Winner of Several Industry Awards
DELEX’s track record of success is reflected in the numerous accolades and awards the company has received. These include recognition as the “Diversity Company of the Year” and “SME Company of the Year” by the Asia CEO Awards, as well as individual honors for its leadership team. These awards affirm DELEX’s position as a top-tier healthcare company in the Philippines.
14. . Asia’s Booming Pharmaceutical Market
With the Asian pharmaceutical market projected to reach US$304.8 billion by 2029, DELEX Pharma is poised to play a key role in this rapidly growing industry. The company’s strategic positioning and expansive product offerings give it a competitive edge as the market continues to grow at a steady pace.
15. Name Change and Ticker Symbol
A formal application to rename BNCM to DELEX and update the ticker symbol will be applied from Q1 2025, aligning with the new direction of the merged company. This rebrand reflects the company’s ambition to further solidify its presence in the global healthcare market and prepare for an exciting phase of expansion.
16. Regulation A Filing and SEC Approval
To support its future growth, DELEX Pharma plans to file for Regulation A with the SEC from March 2025, opening up new avenues for investment and funding. This filing is a crucial step in DELEX’s journey toward achieving its long-term business objectives.
17. Uplist to OTCQB and NASDAQ
DELEX plans to take its corporate visibility to the next level by applying for an uplist to the OTCQB in 2025, with the ultimate goal of listing on the NASDAQ. This move will open the doors for increased capital access and heighten DELEX’s visibility among global investors.
Disclaimer: Forward-Looking Statements
Certain information set forth by BNCM-DELEX group through presentation and publishing including those in websites and in other platforms may contain “forward-looking information,” including “future-oriented financial information,” and “financial outlook,” under applicable securities laws. These statements may contain information about financial prospects, projections, economic conditions, trends and uncertainties, and involve risks. We caution that actual results could differ materially from management experts, depending on the outcome of certain factors. Forward looking statements are provided to understand company’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. Any or all forward-looking statements may or may not turn to be wrong thereby making these statements of no guarantee into its future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties which may cause variations in actual performance in future periods and may differ materially from any projections of future performance or results expressed or implied by such forward-looking statements, thus speaks only as of the date they are made. The Company undertakes no obligation to update or revise forward-looking statements except as required by applicable securities laws.